Long‐term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: An analysis using a Markov chain model

2020 ◽  
Author(s):  
Toshifumi Tada ◽  
Hidenori Toyoda ◽  
Satoshi Yasuda ◽  
Takashi Kumada ◽  
Akemi Kurisu ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Markov Chain ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Markov Chain Model ◽  
Chain Model ◽  
Chronic Hepatitis C Virus ◽  
Long Term Prognosis

scholarly journals Natural history of liver‐related disease in patients with chronic hepatitis C virus infection: An analysis using a Markov chain model

2019 ◽  
Vol 91 (10) ◽  
pp. 1837-1844 ◽  
Author(s):  
Toshifumi Tada ◽  
Hidenori Toyoda ◽  
Satoshi Yasuda ◽  
Nozomi Miyake ◽  
Takashi Kumada ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Markov Chain ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Markov Chain Model ◽  
Chain Model ◽  
Hepatitis C Virus Infection ◽  
Related Disease ◽  
Chronic Hepatitis C Virus ◽  
History Of

scholarly journals Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection

2018 ◽  
Vol 32 (2) ◽  
pp. 253-268 ◽  
Author(s):  
Anne C. Moorman ◽  
Loralee B. Rupp ◽  
Stuart C. Gordon ◽  
Yuna Zhong ◽  
Jian Xing ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Hepatitis C ◽  
Hepatitis C Virus Infection ◽  
Disease Treatment ◽  
Chronic Hepatitis C Virus

Long-term natural history of liver disease in patients with chronic hepatitis B virus infection: an analysis using the Markov chain model

2018 ◽  
Vol 53 (11) ◽  
pp. 1196-1205 ◽  
Author(s):  
Toshifumi Tada ◽  
Takashi Kumada ◽  
Hidenori Toyoda ◽  
Masayuki Ohisa ◽  
Tomoyuki Akita ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Markov Chain ◽  
Liver Disease ◽  
Markov Chain Model ◽  
Chain Model ◽  
Hepatitis B Virus Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus ◽  
History Of

scholarly journals Variant in CD209 promoter is associated with severity of liver disease in chronic hepatitis C virus infection

2010 ◽  
Vol 71 (8) ◽  
pp. 829-832 ◽  
Author(s):  
Elizabeth J. Ryan ◽  
Megan Dring ◽  
Cliona M. Ryan ◽  
Carol McNulty ◽  
Nigel J. Stevenson ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Chronic Hepatitis C ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus

scholarly journals Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus

2004 ◽  
Vol 41 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Angelo Alves de Mattos ◽  
Eliana Buksztejn Gomes ◽  
Cristiane Valle Tovo ◽  
Cláudio Osmar Pereira Alexandre ◽  
José Oscar dos Reis Remião
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Hepatitis C Virus Infection ◽  
Chronic Hepatitis C Virus

BACKGROUND: Considering the immunosuppression of patients with chronic liver disease, their response to vaccination is discussed in literature. AIMS: To evaluate the response of hepatitis B vaccine in patients with chronic hepatitis C virus infection. METHODS: This is a prospective study in which 85 patients with chronic hepatitis C virus infection (46.8 ± 9.4 years, 44.7% males) and 46 healthy adults (36.7 ± 11.1 years; 39.1% males) were evaluated. Confirmation of hepatitis C virus was obtained by the technique of polymerase chain reaction. Viral load was determined by the branched DNA method in 74 patients, and genotype was determined by sequencing in 73 patients. All patients and healthy adults received three doses of Engerix B® vaccine IM (at 0, 30 and 180 days). Serological responses to the vaccine were divided into three categories: seroprotection, when anti-HBs was >100 mUI/mL; seroconversion, when anti-HBs was 10-99 mUI/mL, and non-reagent, when anti-HBs was <10 mUI/mL. RESULTS: The response of hepatitis B vaccine as determined 1 month following dose 3 was seroprotection in 37.7%, seroconversion in 17.6% and non-reagent in 44.7% among patients and 84.8%, 13.0%, 2.2%, respectively in healthy adults. The number of non-reagent responses was significantly higher among those patients with chronic liver disease. Sixty-five patients with chronic hepatitis were compared to 20 compensated cirrhotic patients in concern to the response to vaccine, but no difference was found. The response to vaccine in patients with genotypes 2 or 3 (n = 40) was better than in those with genotype 1 (n = 33). Response was not related to serum HCV-RNA concentration. CONCLUSION: The number of non-responders was higher in patients with chronic hepatitis C virus infection, irrespective of histological status and viral load. It is suggested that such patients should receive a double dose of vaccine, particularly the ones with genotype 1.

Long-term response to interferon alpha is unrelated to“interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection

1999 ◽  
Vol 30 (6) ◽  
pp. 1023-1027 ◽  
Author(s):  
Giovanni Squadrito ◽  
Maria Elena Orlando ◽  
Irene Cacciola ◽  
Maria Grazia Rumi ◽  
Marco Artini ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Interferon Alpha ◽  
Chronic Hepatitis C Virus ◽  
Term Response
Sign in / Sign up

Export Citation Format

Share Document